This alteration triggers accelerated growth and invasive potential, but not necessarily progression from horizontal to vertical growth phases
While it can be combined with IGF-1 LR3, youll need to monitor for IGF-1 overstimulation (e.g., lethargy, joint pain, insulin sensitivity shifts)
A 12-week randomized trial demonstrated: Average weight loss of 2.6 kg in AOD-9604 group (1 mg/day) versus 0.8 kg in placebo group Preferential reduction in abdominal and visceral fat deposits No adverse effects on carbohydrate metabolism or insulin sensitivity Non-dose-dependent effects, with higher doses (10 mg/day) producing less weight loss than lower doses However, a subsequent 24-week Phase III trial with 502 subjects incorporating intensive diet and exercise showed no statistically significant weight loss compared to placebo, leading to development termination in 2007
Side effect profile Both formats produce similar GLP-1-related side effects because they deliver the same active molecule
While it can be disheartening, its also a completely normal part of the weight loss process
Palmitoylcarnitine regulates estrification of lipids and promotes palmitoylation of GAP-43